Mohammad M Ibrahim, Mohamad Nurul Azmi, Maram B Alhawarri, Nik Nur Syazni Nik Mohamed Kamal, Hasan AbuMahmoud
Coughlin SS, Ekwueme DU (2009) Breast cancer as a global health concern. Cancer Epidemiol 33:315–318. https://doi.org/10.1016/j.canep.2009.10.003
[DOI:
10.1016/j.canep.2009.10.003]
Sambi M, Qorri B, Harless W, Szewczuk MR (2019) Therapeutic options for metastatic breast cancer. In: Ahmad A (ed) Breast cancer metastasis and drug resistance. Springer International Publishing, Cham, pp 131–172
[DOI:
10.1007/978-3-030-20301-6_8]
Montemurro F, Di Cosimo S, Arpino G (2013) Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. Ann Oncol 24:2715–2724. https://doi.org/10.1093/annonc/mdt287
[DOI:
10.1093/annonc/mdt287]
Subramaniam S, Bhoo-Pathy N, Taib NA et al (2015) Breast cancer outcomes as defined by the estrogen receptor, progesterone receptor, and human growth factor receptor-2 in a multi-ethnic Asian country. World J Surg 39:2450–2458. https://doi.org/10.1007/s00268-015-3133-2
[DOI:
10.1007/s00268-015-3133-2]
Ali K, Nabeel M, Mohsin F et al (2024) Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies. Med Oncol 41:112. https://doi.org/10.1007/s12032-024-02347-z
[DOI:
10.1007/s12032-024-02347-z]
Sarhangi N, Hajjari S, Heydari SF et al (2022) Breast cancer in the era of precision medicine. Mol Biol Rep 49:10023–10037. https://doi.org/10.1007/s11033-022-07571-2
[DOI:
10.1007/s11033-022-07571-2]
Miricescu D, Diaconu C, Stefani C et al (2020) The serine/threonine protein kinase (Akt)/protein kinase B (PkB) signaling pathway in breast cancer. JMMS 7:34–39. https://doi.org/10.22543/7674.71.P3439
[DOI:
10.22543/7674.71.P3439]
Miricescu D, Totan A, Stanescu-Spinu I-I et al (2020) PI3K/AKT/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects. IJMS 22:173. https://doi.org/10.3390/ijms22010173
[DOI:
10.3390/ijms22010173]
Gao Y, Moten A, Lin H-K (2014) Akt: a new activation mechanism. Cell Res 24:785–786. https://doi.org/10.1038/cr.2014.57
[DOI:
10.1038/cr.2014.57]
Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27:5497–5510. https://doi.org/10.1038/onc.2008.245
[DOI:
10.1038/onc.2008.245]
Cassinelli G, Zuco V, Gatti L et al (2013) Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells. CMC 20:1923–1945. https://doi.org/10.2174/09298673113209990106
[DOI:
10.2174/09298673113209990106]
Hua H, Zhang H, Chen J et al (2021) Targeting Akt in cancer for precision therapy. J Hematol Oncol 14:128. https://doi.org/10.1186/s13045-021-01137-8
[DOI:
10.1186/s13045-021-01137-8]
Ariazi E, Ariazi J, Cordera F, Jordan V (2006) Estrogen receptors as therapeutic targets in breast cancer. CTMC 6:181–202. https://doi.org/10.2174/156802606776173483
[DOI:
10.2174/156802606776173483]
Nagini S (2017) Breast cancer: current molecular therapeutic targets and new players. ACAMC 17:152–163. https://doi.org/10.2174/1871520616666160502122724
[DOI:
10.2174/1871520616666160502122724]
Pawlak KJ, Wiebe JP (2007) Regulation of estrogen receptor (ER) levels in MCF-7 cells by progesterone metabolites. J Steroid Biochem Mol Biol 107:172–179. https://doi.org/10.1016/j.jsbmb.2007.05.030
[DOI:
10.1016/j.jsbmb.2007.05.030]
Mal R, Magner A, David J et al (2020) Estrogen receptor beta (ERβ): a ligand activated tumor suppressor. Front Oncol 10:587386. https://doi.org/10.3389/fonc.2020.587386
[DOI:
10.3389/fonc.2020.587386]
Arpino G, Milano M, De Placido S (2015) Features of aggressive breast cancer. The Breast 24:594–600. https://doi.org/10.1016/j.breast.2015.06.001
[DOI:
10.1016/j.breast.2015.06.001]
Ménard S, Fortis S, Castiglioni F et al (2001) HER2 as a prognostic factor in breast cancer. Oncology 61:67–72. https://doi.org/10.1159/000055404
[DOI:
10.1159/000055404]
He Y, Sun MM, Zhang GG et al (2021) Targeting PI3K/Akt signal transduction for cancer therapy. Sig Transduct Target Ther 6:425. https://doi.org/10.1038/s41392-021-00828-5
[DOI:
10.1038/s41392-021-00828-5]
Yamamoto-Ibusuki M, Arnedos M, André F (2015) Targeted therapies for ER+/HER2- metastatic breast cancer. BMC Med 13:137. https://doi.org/10.1186/s12916-015-0369-5
[DOI:
10.1186/s12916-015-0369-5]
Gallagher T, Derrick I, Durkin PM et al (2010) Intramolecular 1,6-addition to 2-pyridones. Mechanism and synthetic scope. J Org Chem 75:3766–3774. https://doi.org/10.1021/jo100514a
[DOI:
10.1021/jo100514a]
Tamura R, Yamada Y, Nakao Y, Hiyama T (2012) Alkylation of pyridone derivatives by nickel/lewis acid catalysis. Angew Chem Int Ed 51:5679–5682. https://doi.org/10.1002/anie.201200922
[DOI:
10.1002/anie.201200922]
Forrestall KL, Burley DE, Cash MK et al (2021) 2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease. Chem Biol Interact 335:109348. https://doi.org/10.1016/j.cbi.2020.109348
[DOI:
10.1016/j.cbi.2020.109348]
Knoepfel T, Nimsgern P, Jacquier S et al (2020) Target-based identification and optimization of 5-indazol-5-yl pyridones as toll-like receptor 7 and 8 antagonists using a biochemical TLR8 antagonist competition assay. J Med Chem 63:8276–8295. https://doi.org/10.1021/acs.jmedchem.0c00130
[DOI:
10.1021/acs.jmedchem.0c00130]
Reich SH, Sprengeler PA, Chiang GG et al (2018) Structure-based design of pyridone-aminal eFT508 targeting dysregulated translation by selective mitogen-activated protein kinase interacting kinases 1 and 2 (MNK1/2) inhibition. J Med Chem 61:3516–3540. https://doi.org/10.1021/acs.jmedchem.7b01795
[DOI:
10.1021/acs.jmedchem.7b01795]
Good JAD, Silver J, Núñez-Otero C et al (2016) Thiazolino 2-pyridone amide inhibitors of Chlamydia trachomatis infectivity. J Med Chem 59:2094–2108. https://doi.org/10.1021/acs.jmedchem.5b01759
[DOI:
10.1021/acs.jmedchem.5b01759]
Han J, Liu C, Li L et al (2017) Decalin-containing tetramic acids and 4-hydroxy-2-pyridones with antimicrobial and cytotoxic activity from the fungus Coniochaeta cephalothecoides collected in Tibetan plateau (Medog). J Org Chem 82:11474–11486. https://doi.org/10.1021/acs.joc.7b02010
[DOI:
10.1021/acs.joc.7b02010]
Yang W, Zhang B, Tan Q et al (2024) 4-Hydroxy-2-pyridone derivatives with antitumor activity produced by mangrove endophytic fungus Talaromyces sp CY-3. Eur J Med Chem 269:116314. https://doi.org/10.1016/j.ejmech.2024.116314
[DOI:
10.1016/j.ejmech.2024.116314]
Ng PS, Manjunatha UH, Rao SPS et al (2015) Structure activity relationships of 4-hydroxy-2-pyridones: a novel class of antituberculosis agents. Eur J Med Chem 106:144–156. https://doi.org/10.1016/j.ejmech.2015.10.008
[DOI:
10.1016/j.ejmech.2015.10.008]
Zhang Y, Pike A (2021) Pyridones in drug discovery: recent advances. Bioorg Med Chem Lett 38:127849. https://doi.org/10.1016/j.bmcl.2021.127849
[DOI:
10.1016/j.bmcl.2021.127849]
Al-Refai M, Ibrahim MM, Nurul Azmi M et al (2019) The synthesis, characterization, cytotoxic activity assessment and structure-activity relationship of 4-aryl-6-(2,5-dichlorothiophen-3-yl)-2-methoxypyridine-3-carbonitriles. Molecules 24:4072. https://doi.org/10.3390/molecules24224072
[DOI:
10.3390/molecules24224072]
Ibrahim M (2015) One-pot synthesis, characterization and antimicrobial activity of new 3-cyano-4-alkyl-6-(2,5-dichlorothiophen-3-yl)-2(1H)-pyridones. Jordan J Chem 10:98–107
[DOI:
10.12816/0026450]
Al-Refai M, Ibrahim M, Al-Fawwaz A, Geyer A (2018) Synthesis and characterization of new 4-aryl-2-(2-oxopropoxy)-6-(2,5-dichlorothiophene)nicotinonitrile and their furo[2,3-b]pyridine derivatives: assessment of antioxidant and biological activity. Eur J Chem 9:375–381. https://doi.org/10.5155/eurjchem.9.4.375-381.1792
[DOI:
10.5155/eurjchem.9.4.375-381.1792]
Ibrahim MM, Al-Refai M, Azmi MN et al (2019) Synthesis, characterization and cytotoxicity of new nicotinonitriles and their furo[2,3-b]pyridine derivatives. J Iran Chem Soc 16:715–722. https://doi.org/10.1007/s13738-018-1549-y
[DOI:
10.1007/s13738-018-1549-y]
Ghosh PS, Manna K, Banik U et al (2014) Synthetic strategies and pharmacology of 2-oxo-3-cyanopyridine derivatives: a review. Int J Pharm Pharm Sci 6:39–42
Di Paola R, Mazzon E, Paterniti I et al (2011) Olprinone, a PDE3 inhibitor, modulates the inflammation associated with myocardial ischemia–reperfusion injury in rats. Eur J Pharmacol 650:612–620. https://doi.org/10.1016/j.ejphar.2010.10.043
[DOI:
10.1016/j.ejphar.2010.10.043]
Patel K, Patel DK (2016) Medicinal significance, pharmacological activities, and analytical aspects of ricinine: a concise report. J Coast Life Med 4:663–667. https://doi.org/10.12980/jclm.4.2016J6-96
[DOI:
10.12980/jclm.4.2016J6-96]
Zhang X, Zhang J, Liu Y et al (2021) Pirfenidone inhibits fibroblast proliferation, migration or adhesion and reduces epidural fibrosis in rats via the PI3K/AKT signaling pathway. Biochem Biophys Res Commun 547:183–191. https://doi.org/10.1016/j.bbrc.2021.01.055
[DOI:
10.1016/j.bbrc.2021.01.055]
Zhang Y, Zhang Q, Bao J et al (2019) Apiosporamide, A 4-hydroxy-2-pyridone alkaloid, induces apoptosis via PI3K/Akt signaling pathway in osteosarcoma cells. OTT 12:8611–8620. https://doi.org/10.2147/OTT.S218692
[DOI:
10.2147/OTT.S218692]
Koszalka P, Kutryb-Zajac B, Mierzejewska P et al (2022) 4-Pyridone-3-carboxamide-1-β-D-ribonucleoside (4PYR)—a novel oncometabolite modulating cancer-endothelial interactions in breast cancer metastasis. IJMS 23:5774. https://doi.org/10.3390/ijms23105774
[DOI:
10.3390/ijms23105774]
Ruparelia KC, Lodhi S, Ankrett DN et al (2019) The synthesis of 4,6-diaryl-2-pyridones and their bioactivation in CYP1 expressing breast cancer cells. Bioorg Med Chem Lett 29:1403–1406. https://doi.org/10.1016/j.bmcl.2019.03.030
[DOI:
10.1016/j.bmcl.2019.03.030]
Huseyin I, Gulsah B, Merve S (2022) Fused pyridine derivatives: synthesis and biological activities. In: Pal S (ed) Exploring chemistry with pyridine derivatives. IntechOpen, Rijeka, p 7
Kumar GS, Poornachandra Y, Reddy KR et al (2017) Synthesis of novel triazolothione, thiadiazole, triazole-functionalized furo/thieno[2,3- b ]pyridine derivatives and their antimicrobial activity. Synth Commun 47:1864–1873. https://doi.org/10.1080/00397911.2017.1354379
[DOI:
10.1080/00397911.2017.1354379]
Zhang Z, Qiao T, Watanabe K, Tang Y (2020) Concise biosynthesis of phenylfuropyridones in fungi. Angew Chem Int Ed 59:19889–19893. https://doi.org/10.1002/anie.202008321
[DOI:
10.1002/anie.202008321]
Murumkar PR, Ghuge RB, Chauhan M et al (2020) Recent developments and strategies for the discovery of TACE inhibitors. Expert Opin Drug Discov 15:779–801. https://doi.org/10.1080/17460441.2020.1744559
[DOI:
10.1080/17460441.2020.1744559]
Ye N, Qin W, Tian S et al (2020) Small molecules selectively targeting sigma-1 receptor for the treatment of neurological diseases. J Med Chem 63:15187–15217. https://doi.org/10.1021/acs.jmedchem.0c01192
[DOI:
10.1021/acs.jmedchem.0c01192]
Davoren JE, Nason D, Coe J et al (2018) Discovery and lead optimization of atropisomer D1 agonists with reduced desensitization. J Med Chem 61:11384–11397. https://doi.org/10.1021/acs.jmedchem.8b01622
[DOI:
10.1021/acs.jmedchem.8b01622]
Bathula C, Mamidala R, Thulluri C et al (2015) Substituted furopyridinediones as novel inhibitors of α-glucosidase. RSC Adv 5:90374–90385. https://doi.org/10.1039/C5RA19255B
[DOI:
10.1039/C5RA19255B]
Hempel C, Najjar A, Totzke F et al (2016) Discovery of dually acting small-molecule inhibitors of cancer-resistance relevant receptor tyrosine kinases EGFR and IGF-1R. Med Chem Commun 7:2159–2166. https://doi.org/10.1039/C6MD00329J
[DOI:
10.1039/C6MD00329J]
Paruch K, Petrujova M, Nemec V (2015) Furopyridines as inhibitors of protein kinases
Yang B, Vasbinder MM, Hird AW et al (2018) Adventures in scaffold morphing: discovery of fused ring heterocyclic checkpoint kinase 1 (CHK1) inhibitors. J Med Chem 61:1061–1073. https://doi.org/10.1021/acs.jmedchem.7b01490
[DOI:
10.1021/acs.jmedchem.7b01490]
Laxmi DS, Vardhini SV, Guttikonda VR et al (2020) Synthesis of 2-substituted furo[3,2-b]pyridines under Pd/C-Cu catalysis assisted by ultrasound: their evaluation as potential cytotoxic agents. ACAMC 20:932–940. https://doi.org/10.2174/1871520620666200311102304
[DOI:
10.2174/1871520620666200311102304]
Ibrahim MM, Al-Refai M, Al-Fawwaz A et al (2018) Synthesis of fluorescent 1-(3-amino-4-(4-(tert-butyl)phenyl)−6-(p-tolyl)furo[2,3-b]pyridin-2-yl)ethan-1-one: crystal structure, fluorescence behavior, antimicrobial and antioxidant studies. J Fluoresc 28:655–662. https://doi.org/10.1007/s10895-018-2227-2
[DOI:
10.1007/s10895-018-2227-2]
Othman EM, Fayed EA, Husseiny EM, Abulkhair HS (2022) The effect of novel synthetic semicarbazone- and thiosemicarbazone-linked 1,2,3-triazoles on the apoptotic markers, VEGFR-2, and cell cycle of myeloid leukemia. Bioorg Chem 127:105968. https://doi.org/10.1016/j.bioorg.2022.105968
[DOI:
10.1016/j.bioorg.2022.105968]
Ahmed MH, El-Hashash MA, Marzouk MI, El-Naggar AM (2019) Design, synthesis, and biological evaluation of novel pyrazole, oxazole, and pyridine derivatives as potential anticancer agents using mixed chalcone. J Heterocycl Chem 56:114–123. https://doi.org/10.1002/jhet.3380
[DOI:
10.1002/jhet.3380]
Zulkifli NI, Muhamad M, Mohamad Zain NN et al (2020) A bottom-up synthesis approach to silver nanoparticles induces anti-proliferative and apoptotic activities against MCF-7, MCF-7/TAMR-1 and MCF-10A human breast cell lines. Molecules 25:4332. https://doi.org/10.3390/molecules25184332
[DOI:
10.3390/molecules25184332]
Blake JF, Kallan NC, Xiao D et al (2010) Discovery of pyrrolopyrimidine inhibitors of Akt. Bioorg Med Chem Lett 20:5607–5612. https://doi.org/10.1016/j.bmcl.2010.08.053
[DOI:
10.1016/j.bmcl.2010.08.053]
Shiau AK, Barstad D, Radek JT et al (2002) Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol. https://doi.org/10.1038/nsb787
[DOI:
10.1038/nsb787]
Aertgeerts K, Skene R, Yano J et al (2011) Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J Biol Chem 286:18756–18765. https://doi.org/10.1074/jbc.M110.206193
[DOI:
10.1074/jbc.M110.206193]
Berman H, Henrick K, Nakamura H (2003) Announcing the worldwide protein Data Bank. Nat Struct Mol Biol 10:980–980. https://doi.org/10.1038/nsb1203-980
[DOI:
10.1038/nsb1203-980]
Biovia (2020) D. Systèmes
Al-Thiabat MG, Gazzali AM, Mohtar N et al (2021) Conjugated β-cyclodextrin enhances the affinity of folic acid towards FRα: molecular dynamics study. Molecules 26:5304. https://doi.org/10.3390/molecules26175304
[DOI:
10.3390/molecules26175304]
Alhawarri MB, Dianita R, Rawa MSA et al (2023) Potential anti-cholinesterase activity of bioactive compounds extracted from Cassia grandis L.f. and Cassia timoriensis DC. Plants 12:344. https://doi.org/10.3390/plants12020344
[DOI:
10.3390/plants12020344]
Alhawarri MB, Al-Thiabat MG, Dubey A et al (2024) ADME profiling, molecular docking, DFT, and MEP analysis reveal cissamaline, cissamanine, and cissamdine from Cissampelos capensis L.f. as potential anti-Alzheimer’s agents. RSC Adv 14:9878–9891. https://doi.org/10.1039/D4RA01070A
[DOI:
10.1039/D4RA01070A]
Amir Rawa MS, Al-Thiabat MG, Nogawa T et al (2022) Naturally occurring 8ß,13ß-kaur-15-en-17-al and anti-malarial activity from Podocarpus polystachyus leaves. Pharmaceuticals 15:902. https://doi.org/10.3390/ph15070902
[DOI:
10.3390/ph15070902]
Dolinsky TJ, Czodrowski P, Li H et al (2007) PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations. Nucleic Acids Res 35:W522–W525. https://doi.org/10.1093/nar/gkm276
[DOI:
10.1093/nar/gkm276]
Larue L, Kenzhebayeva B, Al-Thiabat MG et al (2023) tLyp–1: a peptide suitable to target NRP–1 receptor. Bioorg Chem 130:106200. https://doi.org/10.1016/j.bioorg.2022.106200
[DOI:
10.1016/j.bioorg.2022.106200]
Yunos NM, Al-Thiabat MG, Sallehudin NJ, Wahab AH (2024) Quassinoids from Eurycoma longifolia as potential dihydrofolatereductase inhibitors: a computational study. CPB. https://doi.org/10.2174/0113892010273336240221101506
[DOI:
10.2174/0113892010273336240221101506]
Olsson MHM, Søndergaard CR, Rostkowski M, Jensen JH (2011) PROPKA3: consistent treatment of internal and surface residues in empirical p K predictions. J Chem Theory Comput 7:525–537. https://doi.org/10.1021/ct100578z
[DOI:
10.1021/ct100578z]
Williams CJ, Headd JJ, Moriarty NW et al (2018) MolProbity: more and better reference data for improved all-atom structure validation. Protein Sci 27:293–315. https://doi.org/10.1002/pro.3330
[DOI:
10.1002/pro.3330]
Al-Thiabat MG, Saqallah FG, Gazzali AM et al (2021) Heterocyclic substitutions greatly improve affinity and stability of folic acid towards FRα an in silico insight. Molecules 26:1079. https://doi.org/10.3390/molecules26041079
[DOI:
10.3390/molecules26041079]
Alidmat MM, Khairuddean M, Wahab HA et al (2022) Synthesis, characterization, molecular docking and cytotoxicity evaluation of new thienyl chalcone derivatives against breast cancer cells. Sys Rev Pharm 13:1–11
Morris GM, Huey R, Lindstrom W et al (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30:2785–2791. https://doi.org/10.1002/jcc.21256
[DOI:
10.1002/jcc.21256]
Hou X, Du J, Zhang J et al (2013) How to improve docking accuracy of AutoDock4.2: a case study using different electrostatic potentials. J Chem Inf Model 53:188–200. https://doi.org/10.1021/ci300417y
[DOI:
10.1021/ci300417y]
Ross BJ (2019) A Lamarckian evolution strategy for genetic algorithms. In: Chambers L (ed) Practical handbook of genetic algorithm, 1st edn. CRC Press, Boca Raton
Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7:42717. https://doi.org/10.1038/srep42717
[DOI:
10.1038/srep42717]
Alhawarri MB, Olimat S (2024) Potential serotonin 5-HT2A receptor agonist of psychoactive components of silene undulata aiton: LC-MS/MS, ADMET, and molecular docking studies. CPB. https://doi.org/10.2174/0113892010299804240324140017
[DOI:
10.2174/0113892010299804240324140017]
Elhassanny AEM, Soliman E, Marie M et al (2020) Heme-dependent er stress apoptosis: a mechanism for the selective toxicity of the dihydroartemisinin, NSC735847, in colorectal cancer cells. Front Oncol 10:965. https://doi.org/10.3389/fonc.2020.00965
[DOI:
10.3389/fonc.2020.00965]
Routholla G, Pulya S, Patel T et al (2021) Design, synthesis and binding mode of interaction of novel small molecule o-hydroxy benzamides as HDAC3-selective inhibitors with promising antitumor effects in 4T1-Luc breast cancer xenograft model. Bioorg Chem 117:105446. https://doi.org/10.1016/j.bioorg.2021.105446
[DOI:
10.1016/j.bioorg.2021.105446]
Kaur T, Madgulkar A, Bhalekar M, Asgaonkar K (2019) Molecular docking in formulation and development. CDDT 16:30–39. https://doi.org/10.2174/1570163815666180219112421
[DOI:
10.2174/1570163815666180219112421]
Gonzalez-Ruiz D, Gohlke H (2006) Targeting protein-protein interactions with small molecules: challenges and perspectives for omputational binding epitope detection and ligand finding. CMC 13:2607–2625. https://doi.org/10.2174/092986706778201530
[DOI:
10.2174/092986706778201530]
Glen R, Allen S (2003) Ligand-protein docking: cancer research at the interface between biology and chemistry. CMC 10:763–777. https://doi.org/10.2174/0929867033457809
[DOI:
10.2174/0929867033457809]
Mirza Z, Schulten H-J, Farsi HM et al (2014) Impact of S100A8 expression on kidney cancer progression and molecular docking studies for kidney cancer therapeutics. Anticancer Res 34:1873–1884
[PMID:
24692722]
Caldwell GW (2000) Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens. Curr Opin Drug Discov Devel 3:30–41
[PMID:
19649835]
Putra IMR, Lestari IA, Fatimah N et al (2024) Bioinformatics and in vitro study reveal ERα as the potential target gene of honokiol to enhance trastuzumab sensitivity in HER2+ trastuzumab-resistant breast cancer cells. Comput Biol Chem 111:108084. https://doi.org/10.1016/j.compbiolchem.2024.108084
[DOI:
10.1016/j.compbiolchem.2024.108084]
Davis NM, Sokolosky M, Stadelman K et al (2014) Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget 5:4603–4650. https://doi.org/10.18632/oncotarget.2209
[DOI:
10.18632/oncotarget.2209]
George B, Gui B, Raguraman R et al (2022) AKT1 transcriptomic landscape in breast cancer cells. Cells 11:2290. https://doi.org/10.3390/cells11152290
[DOI:
10.3390/cells11152290]
Ju X, Katiyar S, Wang C et al (2007) Akt1 governs breast cancer progression in vivo. Proc Natl Acad Sci USA 104:7438–7443. https://doi.org/10.1073/pnas.0605874104
[DOI:
10.1073/pnas.0605874104]
Steelman LS, Stadelman KM, Chappell WH et al (2008) Akt as a therapeutic target in cancer. Expert Opin Ther Targets 12:1139–1165. https://doi.org/10.1517/14728222.12.9.1139
[DOI:
10.1517/14728222.12.9.1139]
Thaler S, Schmidt M, Robwag S et al (2017) Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells. Oncotarget 8:72281–72301. https://doi.org/10.18632/oncotarget.20261
[DOI:
10.18632/oncotarget.20261]
Ganguly D (2011) Expression of the cytosolic phospholipase A2 isozymes in the human breast cancer cell line models MDA-MB 231 and MCF-7 and the normal breast cell line model MCF-10A. West Virginia University Libraries, Morgantown
[DOI:
10.33915/etd.4716]
Lam L, Hu X, Aktary Z et al (2009) Tamoxifen and ICI 182,780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ERα. Breast Cancer Res Treat 118:605–621. https://doi.org/10.1007/s10549-008-0231-y
[DOI:
10.1007/s10549-008-0231-y]
Kaboli PJ, Imani S, Jomhori M, Ling K-H (2021) Chemoresistance in breast cancer: PI3K/Akt pathway inhibitors vs the current chemotherapy. Am J Cancer Res 11:5155–5183
[PMID:
34765318]
Owonikoko TK, Khuri FR (2013) Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation. Am Soc Clin Oncol Educ Book 33:e395–e401. https://doi.org/10.14694/EdBook_AM.2013.33.e395
[DOI:
10.14694/EdBook_AM.2013.33.e395]
Yunos NM, Wahab HA, Al-Thiabat MG et al (2023) In vitro and in silico analysis of the anticancer effects of eurycomanone and eurycomalactone from Eurycoma longifolia. Plants 12:2827. https://doi.org/10.3390/plants12152827
[DOI:
10.3390/plants12152827]
Ntie-Kang F, Nyongbela KD, Ayimele GA, Shekfeh S (2019) Drug-likeness properties of natural compounds. Phys Sci Rev. https://doi.org/10.1515/psr-2018-0169
[DOI:
10.1515/psr-2018-0169]
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169–409X(96), 00423–1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1. Adv Drug Deliv Rev 46:3–26. https://doi.org/10.1016/S0169-409X(00)00129-0
[DOI:
10.1016/S0169-409X(00)00129-0]
Zhou S-F, Xue CC, Yu X-Q et al (2007) Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 29:687–710. https://doi.org/10.1097/FTD.0b013e31815c16f5
[DOI:
10.1097/FTD.0b013e31815c16f5]
Ndombera FT, Maiyoh GKK, Tuei VC (2019) Pharmacokinetic, physicochemical and medicinal properties of N-glycoside anti-cancer agent more potent than 2-deoxy-D-glucose in lung cancer cells. JPP. https://doi.org/10.17265/2328-2150/2019.04.003
[DOI:
10.17265/2328-2150/2019.04.003]
